Magnetoresistance characteristics of Fe3Si/CaF2/Fe3Si heterostructures grown on Si(111) by molecular beam epitaxy

AbstractFe3Si/CaF2/Fe3Si magnetic tunnel junctions (MTJs) have been investigated to demonstrate the tunnel magnetoresistance effects. We fabricated Fe3Si(20 nm)/CaF2(2 nm)/Fe3Si(15 nm) heterostructures epitaxially on a Si(111) substrate by molecular beam epitaxy. The current-voltage characteristics for the MTJs measured at room temperature (RT) were well fitted to Simmons’ equation. The fitting yields the barrier height φ=2.5 eV and the barrier thickness d=1.26 nm. The magnetoresistance ratio for the MTJs were approximately 0.28% under a bias voltage of 20 mV at RT

Polycrystalline thin-film transistors fabricated on high-mobility solid-phase-crystallized Ge on glass

Low-temperature formation of Ge thin-film transistors (TFTs) on insulators has been widely investigated to improve the performance of Si large-scale integrated circuits and mobile terminals. Here, we studied the relationship between the electrical properties of polycrystalline Ge and its TFT performance using high-mobility Ge formed on glass using our recently developed solid-phase crystallization technique. The field-effect mobility μFE and on/off currents of the accumulation-mode TFTs directly reflected the Hall hole mobility μHall, hole concentration, and film thickness of Ge. By thinning the 100-nm thick Ge layer with a large grain size (3.7 μm), we achieved a high μHall (190 cm2/Vs) in a 55-nm thick film that was almost thin enough to fully deplete the channel. The TFT using this Ge layer exhibited both high μFE (170 cm2/Vs) and on/off current ratios (∼102). This is the highest μFE among low-temperature (<500 °C) polycrystalline Ge TFTs without minimizing the channel region (<1 μm)

Spin and orbital magnetic moments of molecular beam epitaxy γ′-Fe4N films on LaAlO3(001) and MgO(001) substrates by x-ray magnetic circular dichroism

10-nm-thick γ′-Fe4N films were grown epitaxially on LaAlO3(001) and MgO(001) substrates by molecular beam epitaxy using solid Fe and a radio-frequency NH3 plasma. The lattice mismatch of these substrates to γ′-Fe4N is 0% and 11%, respectively. Spin and orbital magnetic moments of these γ′-Fe4N epitaxial films were deduced by x-ray magnetic circular dichroism measurements at 300 K. The total magnetic moments are almost the same for the two substrates, that is, 2.44±0.06 μB and 2.47±0.06 μB, respectively. These values are very close to those predicted theoretically, and distinctively larger than that for α-Fe

‘A phase II study of oral uracil/ftorafur (UFT®) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'

This phase II trial was performed to evaluate the efficacy and tolerability of a new combination of Uracil/Ftorafur (UFT®)/leucovorin (LV) and oxaliplatin in patients (pts) with metastatic colorectal cancer (MCRC) who had not received prior chemotherapy for metastatic disease. Between February 2002 and October 2002, 64 patients received UFT® 300 mg m−2 day−1 and LV 90 mg day−1 from day 1 to day 14 combined with oxaliplatin 130 mg m−2 on day 1, every 3 weeks. All patients were evaluable for safety analysis and 58 of 64 patients were eligible for efficacy. Responses were reviewed by an independent review committee. Of the 58 per-protocol defined assessable patients, 1 complete response and 20 partial responses were observed yielding a response rate of 34% (95% CI: 22–47). The median response duration was 8.74 months (range 1.6–14). The median time to progression and the median survival were 5.88 months (95% CI: 4.34–8.21) and 18.2 months (95% CI: 10–20.7), respectively. Diarrhoea and peripheral neuropathy were the most frequent and predictable toxicities. These events were reversible, noncumulative and manageable. Grade 3 diarrhoea occurred in only 11% of the patients. No grade 4 gastrointestinal toxicity was reported in the study. The incidence of grade 3/4 (National Cancer Institute Common Toxicity Criteria 2: NCI-CTC 2) peripheral neuropathy was 15%. Haematological toxicity was of mild to moderate intensity with 10% of the patients with Grade 3/4 neutropenia without any episode of complication. The TEGAFOX regimen, a new combination using UFT®/LV and oxaliplatin every 3 weeks is feasible on an outpatient basis. The combination is safe and active and may offer a promising alternative to the intravenous route. Nevertheless this efficacy results should be confirmed by randomized phase III trials

Modelling Strategies for Predicting the Residual Strength of Impacted Composite Aircraft Fuselages

Aeronautic Certification rules established for the metallic materials are not convenient for the composite structures concerning the resistance against impact. The computerbased design is a new methodology that is thought about to replace the experimental tests. It becomes necessary for numerical methods to be robust and predictive for impact. Three questions are addressed in this study: (i) can a numerical model be “mechanically intrinsic” to predict damage after impact, (ii) can this model be the same for a lab sample and a large structure, and (iii) can the numerical model be predictive enough to predict the Compression After Impact (CAI)? Three different computational strategies are used and compared: a Cohesive Model (CM), a Continuous Damage Model (CDM) coupling failure modes and damage, and a Mixed Methodology (MM) using the CDM for delamination initiation and the CM for cracks propagation. The first attempts to use the Smooth Particle Hydrodynamics method are presented. Finally, impact on a fuselage is modelled and a numerical two-stage strategy is developed to predict the CAI

Protective effect of geranylgeranylacetone, an inducer of heat shock protein 70, against drug-induced lung injury/fibrosis in an animal model

<p>Abstract</p> <p>Background</p> <p>To determine whether oral administration of geranylgeranylacetone (GGA), a nontoxic anti-ulcer drug that is an inducer of heat shock protein (HSP) 70, protects against drug-induced lung injury/fibrosis <it>in vivo</it>.</p> <p>Methods</p> <p>We used a bleomycin (BLM)-induced lung fibrosis model in which mice were treated with oral 600 mg/kg of GGA before and after BLM administration. Inflammation and fibrosis were evaluated by histological scoring, hydroxyproline content in the lung and inflammatory cell count, and quantification by ELISA of macrophage inflammatory protein-2 (MIP-2) in bronchoalveolar lavage fluid. Apoptosis was evaluated by the TUNEL method. The induction of HSP70 in the lung was examined with western blot analysis and its localization was determined by immunohistochemistry.</p> <p>Results</p> <p>We confirmed the presence of inflammation and fibrosis in the BLM-induced lung injury model and induction of HSP70 by oral administration of GGA. GGA prevented apoptosis of cellular constituents of lung tissue, such as epithelial cells, most likely related to the <it>de novo </it>induction of HSP70 in the lungs. GGA-treated mice also showed less fibrosis of the lungs, associated with the findings of suppression of both production of MIP-2 and inflammatory cell accumulation in the injured lung, compared with vehicle-treated mice.</p> <p>Conclusion</p> <p>GGA had a protective effect on drug-induced lung injury/fibrosis. Disease-modifying antirheumatic drugs such as methotrexate, which are indispensable for the treatment of rheumatoid arthritis, often cause interstitial lung diseases, an adverse event that currently cannot be prevented. Clinical use of GGA for drug-induced pulmonary fibrosis might be considered in the future.</p